Outlook Therapeutics, Inc. (OTLK) News
Filter OTLK News Items
OTLK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OTLK News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest OTLK News From Around the Web
Below are the latest news stories about OUTLOOK THERAPEUTICS INC that investors may wish to consider to help them evaluate OTLK as an investment opportunity.
Outlook Therapeutics® Participates in Virtual Investor “What This Means” SegmentJedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment o |
Outlook Therapeutics Stock Surges on Positive Outlook Despite LossOutlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company that focuses on retinal diseases saw its stock price upped 18.24% on Friday after its financial results for fiscal years 2024 announced despite net loss. For the fiscal year 2024, Outlook Therapeutics booked net loss of $75.4 million compared to loss of $59 million in the previous year. Despite deeper loss, the loss per share reduced to $4.06 only from $4.72, as the result of reverse stock split that took place on March 2024. |
Outlook Therapeutics Reports 2024 Financial ResultsOutlook Therapeutics ( (OTLK) ) has released its Q4 earnings. Here is a breakdown of the information Outlook Therapeutics presented to its investors. Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for retinal diseases, particularly wet age-related macular degeneration (AMD), with its product LYTENA V A™ being the first approved ophthalmic formulation of bevacizumab in the EU and UK. The company recently announced its financial results for |
Outlook Therapeutics provides ONS-5010/LYTENAVA updateIn May 2024, the European Commission granted Marketing Authorization for LYTENAVA for the treatment of wet AMD in the EU. Additionally, in July 2024, the UK Medicines and Healthcare products Regulatory Agency granted Marketing Authorization for LYTENAVA for the same indication in the UK. In December 2024, the National Institute for Health and Care Excellence recommended LYTENAVA as an option for the treatment of wet AMD. Plans for a potential 2025 launch in the UK and Germany are ongoing. Outloo |
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate UpdateLYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earli |
Outlook Therapeutics® Streamlines OperationsFull NORSE EIGHT Data Readout Expected January 2025ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that following an internal strategic review, the management team and Board |
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDFirst positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000 new wet AMD patients each year in the UK who could benefit from treatment1 ISELIN, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the |
Outlook Therapeutics® Announces Executive Leadership TransitionISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company’s President and Chief Executive Officer (C |
Outlook Therapeutics price target lowered to $9 from $50 at BTIGBTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The firm says ONS-5010 did not surpass the 95% threshold for the primary endpoint in NORSE EIGHT despite the difference between ONS-5010 and ranibizumab falling within the pre-specified noninferiority margin at eight weeks. Despite NORSE EIGHT technically not meeting its primary endpoint, BTIG remains Buy rated. Outlook is now trading at a zero enterprise value, there is still |
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD StudyOutlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD. |